H5O0.F Argent BioPharma Limited

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
0.0105 EUR
Close of Nov 12, 2026
0.0100 0.0550
Market cap
EUR 1.24M
P/E
-
P/B
8.64x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is H5O0.F undervalued?

Graham number

The Graham number of Argent BioPharma Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Argent BioPharma Limited fundamental analysis

No fundamental analysis for Argent BioPharma Limited yet.

Argent BioPharma Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Argent BioPharma Limited

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA c…

Full company profile